ライフサイエンスコーパス: WBC count

1 2.49, p = 0.0001 for the highest quintile of WBC count).

2 ate dehydrogenase, beta-2 microglobulin, and WBC count).

3 ctively) and were not associated with age or WBC count.

4 C count and of the mean of baseline + year 3 WBC count.

5 or high risk (HR) on the basis of diagnostic WBC count.

6 symptoms were not associated with hs-CRP or WBC count.

7 esponses occurred in AML with low presenting WBC count.

8 pronounced in those with progressively lower WBC counts.

9 -165C>T)] was associated with an increase in WBC counts.

10 Higher expression was associated with higher WBC counts.

11 , which have hindered their use to determine WBC counts.

12 association between the MD and both PLT and WBC counts.

13 netic classifier, MRD, and white blood cell (WBC) count.

14 the secondary exposure was white blood cell (WBC) count.

15 , platelet count (PLT) and white blood cell (WBC) count.

16 une (AI) conditions affect white blood cell (WBC) counts.

17 in patients with a higher WBC count (0% for WBC count 0 to 5x10(9)/L, 4.9% for WBC count 5 to 10x10(

18 o associated with a higher WBC count (0% for WBC count 0 to 5x10(9)/L, 5.2% for WBC count 5 to 10x10(

19 rates were higher in patients with a higher WBC count (0% for WBC count 0 to 5x10(9)/L, 4.9% for WBC

20 e or shock was also associated with a higher WBC count (0% for WBC count 0 to 5x10(9)/L, 5.2% for WBC

21 4.9% for WBC count 5 to 10x10(9)/L, 3.8% for WBC count 10 to 15x10(9)/L, 10.4% for WBC count >15x10(9

22 5.2% for WBC count 5 to 10x10(9)/L, 6.1% for WBC count 10 to 15x10(9)/L, 17.1% for WBC count >15x10(9

23 parent thrombus was associated with a higher WBC count (11.5+/-5.2x10(9)/L, n=290, versus 10.7+/-3.5x

24 xin(+) patients had higher white blood cell (WBC) counts (12.5 x 10(3) versus 9.3 x 10(3) cells/mul;

25 0.5 +/- 8.8 days, baseline white blood cell [WBC] count 15.3 +/- 7.1 10(9)/L) vs 29 control patients

26 .04), a lower nadir in the white blood cell (WBC) count (2,818 versus 3,558 cells/microliter; P = 0.0

27 Median age was 72 and 74 years, and median WBC count 32.5 x 10(9)/L and 31.2 x 10(9)/L in the DAC a

28 hose with a clinical history of isolated low WBC count, 34 of 35 (97%) had the CC genotype vs 243 of

29 gnificant greater percent reduction in total WBC count (- 35% [- 48 to - 24] vs. - 21% [- 34 to - 10]

30 dian age, 54 years; median white blood cell [WBC] count 4,500/microL).

31 t (0% for WBC count 0 to 5x10(9)/L, 4.9% for WBC count 5 to 10x10(9)/L, 3.8% for WBC count 10 to 15x1

32 t (0% for WBC count 0 to 5x10(9)/L, 5.2% for WBC count 5 to 10x10(9)/L, 6.1% for WBC count 10 to 15x1

33 a higher median diagnostic white blood cell (WBC) count (71.5 vs 19.6 x 10(9)/L; P =.005) and lower c

34 o-extraction time 8.0 +/- 5.7 days, baseline WBC count 9.9 +/- 4.9 10(9)/L).

35 Interestingly, the WBC count, a systemic inflammatory biomarker, attenuated

36 the variation in baseline white blood cell (WBC) count, a characteristic that correlates with mortal

37 ificant calcium, phosphorus, electrolyte, or WBC count abnormalities were encountered.

38 ed infection, CRP levels 10 mg/L, and higher WBC count affected unfavourable outcome on discharge.

39 statistically significant decrease in total WBC counts among exposed workers [IL-1A (-889C>T), IL-4

40 effect of birth weight on white blood cell (WBC) count among blacks and whites was examined in 2,080

41 Periodontitis may be directly related to WBC count and %neutrophils and inversely related to %lym

42 trast, periodontitis was directly related to WBC count and %neutrophils and inversely related to %lym

43 There was poor correlation between the WBC count and absolute neutrophil counts (ANCs) and both

44 The WBC count and all-cause, cardiovascular, and cancer mort

45 We examined the relationship between the WBC count and angiographic findings to gain insight into

46 ion), and available laboratory data (such as WBC count and CRP).

47 ers, assessment of two inflammatory markers, WBC count and CRP, can be used to stratify patients acro

48 notype who underwent BMB for an isolated low WBC count and had a normal biopsy result compared with t

49 tors, there was a direct association between WBC count and incidence of coronary heart disease (p < 0

50 The association between WBC count and MDS disappeared when further adjusted for

51 same gene or group of genes influences both WBC count and mean platelet volume (MPV).

52 ell (WBC) count and the relationship between WBC count and mortality between 1958 and 2002.

53 hazards associated with deciles of baseline WBC count and of the mean of baseline + year 3 WBC count

54 tudy evaluated the relation between baseline WBC count and other risk factors, as well as subclinical

55 fied the inverse association between MDS and WBC count and partially accounted for the association wi

56 Comparisons of mean WBC count and platelet nadirs for L-PAM alone and L-PAM

57 However, the relationship between WBC count and prognosis following AMI is less clear.

58 ence is increasing for a correlation between WBC count and thrombosis, but prospective data are lacki

59 m3), total protein (>2.5 g/dL), and combined WBC count and total protein (45.8%, 74.4%, and 81.3%, re

60 Women of African ancestry (AA) have lower WBC counts and are more likely to have treatment delays

61 elationship between the normalization of CSF WBC counts and CD4+ T cell counts may indicate continued

62 Among those living with HIV, CSF WBC counts and CSF-VDRL reactivity were more likely to n

63 te observed among AMI patients with elevated WBC counts and helps explain the growing body of literat

64 effusions with relatively low pleural fluid WBC counts and LDH levels.

65 Red marrow dose, baseline platelet or WBC counts and multiple bone or marrow (or both) metasta

66 The correlations between WBC counts and risk factors were similar in both the ent

67 Similarly, there is a correlation between WBC counts and scintigraphy in most segments of the larg

68 genetic mechanisms that regulate circulating WBC counts and suggest a prominent shared genetic archit

69 ationship between baseline white blood cell (WBC) count and angiographic and clinical outcomes in pat

70 be an interaction between white blood cell (WBC) count and bivalirudin for the risk of mortality, an

71 L) were analyzed for total white blood cell (WBC) count and differential cell count, along with gelat

72 ed the association between white blood cell (WBC) count and incidence of coronary heart disease and i

73 redictive ability of total white blood cell (WBC) count and its subtypes for risk of death or myocard

74 had a significantly lower white blood cell (WBC) count and lactate dehydrogenase (LDH) level than di

75 atory responses [change in white blood cell (WBC) count and neutrophil activity], and that these resp

76 ul were the synovial fluid white blood cell (WBC) count and percentage of polymorphonuclear cells fro

77 gated the secular trend in white blood cell (WBC) count and the relationship between WBC count and mo

78 n was assessed using total white blood cell (WBC) count and WBC sub-populations (neutrophils, lymphoc

79 ration, hematocrit levels, white blood cell (WBC) counts and platelet counts in 31,340 individuals ge

80 t therapy, grade 3/4 hepatic encephalopathy, WBC count, and albumin.

81 ivariable Cox regression analysis, sex, age, WBC count, and cytogenetic risk category were related to

82 sex, blood pressure, serum HDL cholesterol, WBC count, and history of current cigarette smoking; and

83 smoking, higher CRP, factor VII, fibrinogen, WBC count, and lower albumin and hemoglobin levels remai

84 range, 17 to 85 years), performance status, WBC count, and mutation status of NPM1, CEBPA, and FLT3-

85 The addition of patients' age, gender, WBC count, and peripheral oxygen saturation increased th

86 hsCRP, WBC count, and serum albumin were measured at baseline i

87 (9%) had clinical histories of isolated low WBC counts, and 364 (91%) had other histories.

88 ue Index (PI), Gingival Index (GI), systemic WBC counts, and peripheral neutrophil oxidative activity

89 en race and treatment discontinuation/delay, WBC counts, and survival in women enrolled onto breast c

90 otein (CRP) concentration, white blood cell (WBC) count, and absolute neutrophil cell (ANC) count for

91 C-reactive protein (CRP), white blood cell (WBC) count, and absolute neutrophil count (ANC) despite

92 h age at presentation, low white blood cell (WBC) count, and low fluorescence intensity of surface CD

93 monocyte percentage, MDW, white blood cell (WBC) count, and neutrophil to lymphocyte ratio (NLR).

94 ein (hsCRP) levels, higher white blood cell (WBC) counts, and lower serum albumin levels, are associa

95 White blood cell (WBC) count appears to predict total mortality and corona

96 Higher WBC counts are associated with higher mortality in succe

97 (99m)Tc-WBC scintigraphy, ESR, and WBC counts are good indicators of the inflammatory activ

98 Platelet (PLT) and white blood cell (WBC) counts are 2 markers of inflammation and have been

99 e, 0.63) followed by albumin, bilirubin, and WBC count (area under the receiver operating characteris

100 outcome or add to the value of an increased WBC count as a negative prognostic indicator in APL pati

101 eic HCT, ELN favorable-risk group, and lower WBC counts as significant favorable factors.

102 ions differed, as did Pao2 to Fio2 ratio and WBC count at admission.

103 hensive risk-stratification model, including WBC count at diagnosis and MRD at the end of induction,

104 include patients 1 to 9 years of age with a WBC count at diagnosis less than 50,000/microL.

105 P = .0001), independent of age (P = .25) and WBC count at presentation (P = .003).

106 FHIT methylation was associated with high WBC counts at diagnosis, a known prognostic indicator.

107 In the cases, white blood cells (WBC) count at diagnosis was compared to prediagnosis; an

108 spectively) and had higher white blood cell (WBC) counts at diagnosis (median, 23.7 x 109/L and 35.7

109 ents with ALL in CR2 (1) for patients with a WBC count (at diagnosis) of 20 x 10(9)/L or higher (DFS,

110 hsCRP), lipid profile, and white blood cell (WBC) count, at baseline and 1, 3, and 6 months.

111 Filgrastim increased WBC counts (baseline median, 13.3x109/L; median peak, 43

112 ere were no differences in age or presenting WBC counts between the cases with or without positive ne

113 In multivariate analyses, peak WBC count, birth weight, intubation, and receipt of nitr

114 bles: red marrow dose, baseline platelet and WBC counts, bone or marrow (or both) metastases, prior c

115 els positively correlated with the NIHSS and WBC count but negatively correlated with total cholester

116 ling and other patient populations that need WBC counts but lack access to clinical facilities.

117 dual variation in baseline white blood cell (WBC) counts, but its clinical significance is uncharacte

118 low-frequency power by 90% (P = 0.01), total WBC count by 139% (P = 0.006), and lymphocyte count by 1

119 artial thromboplastin time) or inflammation (WBC count, C-reactive protein) did not discriminate betw

120 luation (APACHE-II) score, white blood cell (WBC) count, c-reactive protein (CRP), tumor necrosis fac

121 duals and hospitalized patients with similar WBC counts can be robustly classified based on their WBC

122 no differences in initial white blood cell (WBC) count, central nervous system disease, and risk gro

123 del of survival adjusted for age group, sex, WBC count, chloroma, CNS involvement, and French-America

124 ults for biopsies performed for isolated low WBC counts compared with 134 of 243 individuals (55%) wi

125 WBC counts correlated (p < 0.01) positively with coagula

126 In contrast, WBC counts correlated negatively with high density lipop

127 operative Oncology Group performance status, WBC count, creatinine clearance, albumin, AST, number of

128 by prognostic factors in addition to age and WBC count criteria, and that a common set of prognostic

129 nts with T-cell ALL based on the uniform age/WBC count criteria.

130 d 8 other prognostic factors, including age, WBC count, cytogenetics, and gene mutations, into surviv

131 utropenia (42%), thrombocytopenia (38%), and WBC count decreased (34%).

132 king status (in adolescents and adults), the WBC count decreased across quartiles of increasing birth

133 The median WBC count decreased from 36,900/microL before treatment

134 n 21.1%; 27.6% had a >20% increase), whereas WBC count decreased in the PMD arm (mean 8.35%; only 7.7

135 label-free smartphone based electrochemical WBC counting device on microporous paper with patterned

136 Elevated WBC count during follow-up was correlated with thrombosi

137 Elevation of the white blood cell (WBC) count during acute myocardial infarction (AMI) is a

138 Changes in platelet and white blood cell (WBC) counts during CRRT could identify patients at risk

139 onal inflammatory markers (white blood cell [WBC] count, erythrocyte sedimentation rate [ESR], C-reac

140 nce (HOMA-IR), an elevated white blood cell (WBC) count, experience with hysterectomy, being a non-dr

141 C-reactive protein (CRP), white blood cell (WBC) count, fibrinogen, factor VII, albumin, and hemoglo

142 ribution width alone and in combination with WBC count for early sepsis detection in the emergency de

143 ive values of a normal CSF white blood cell (WBC) count for ME panel targets were 100% (195/195) for

144 c variation in circulating white blood cell (WBC) counts from large samples of otherwise healthy indi

145 se variants in CXCR2 associated with reduced WBC count (gene-based P = 2.6 x 10(-13)).

146 Age, initial WBC count, genetic aberrations, and minimal residual dis

147 Other outcomes included weekly WBC counts, graft incorporation, and quantitative cultur

148 ed ASXL1 mutations, age older than 65 years, WBC count greater than 15 x10(9)/L, platelet count less

149 ntial thrombocythaemia and white blood cell (WBC) count greater than 10 x 10(9) cells/L.

150 0) and increased odds of being in the lowest WBC-count group (IMI: odds ratio = 1.41; 95% confidence

151 6) with high-risk ALL (aged 1 to 9 years and WBC count > or = 50,000/microL or age > or = 10 years, e

152 olute neutrophil count >/= 10,000/mm(3) or a WBC count >/= 10,000/mm(3) was reached, both counts serv

153 Patients harboring a WBC count >/=200 x 10(9)/L, gHiR classifier, and MRD >/=

154 When combined with MRD and a WBC count >/=200 x 10(9)/L, it identifies a significant

155 1% for WBC count 10 to 15x10(9)/L, 17.1% for WBC count >15x10(9)/L; P<0.001), an observation that rem

156 8% for WBC count 10 to 15x10(9)/L, 10.4% for WBC count >15x10(9)/L; P=0.03).

157 h IG/TR positivity after cycle 2 and initial WBC count >=30 x 10(9)/L predicted poorer DFS, enabling

158 diagnosis was defined as a white blood cell (WBC) count >20/uL, a CSF protein reading >50 mg/dL, or a

159 Patients with white blood cell (WBC) counts >50,000/microL began ATRA on day 1 and G-CSF

160 African Americans in the highest quartile of WBC count (> or =7,000 cells/mm(3)) had 1.9 times the ri

161 ed models (P < .01); the highest quartile of WBC counts (>/=6500 cells/microL) was associated with in

162 mon ascitic fluid tests of white blood cell (WBC) count (>500/mm3), total protein (>2.5 g/dL), and co

163 An elevated WBC count has been associated with cardiovascular risk,

164 A higher white blood cell (WBC) count has been shown to be a risk factor for myocar

165 iation of TE with elevated white blood cell (WBC) counts has been suggested by retrospective studies,

166 Elevations in WBC count have been associated with the development of A

167 e vs 243 of 364 (67%) of those without a low WBC count history.

168 spital lengths of stay) and incremental peak WBC counts (hospital length of stay only).

169 sed systemic inflammation as depicted by the WBC count in childhood and adulthood, thereby potentiall

170 , birth weight was inversely associated with WBC count in children (beta coefficients (unit, cells/mi

171 mportance of controlling both hematocrit and WBC count in disease management.

172 re each independently associated with higher WBC counts in adjusted models (P < .01); the highest qua

173 e diseases showed associations with measured WBC counts in ARIC and BioVU.

174 used to test for associations with measured WBC counts in individuals of European ancestry in a comm

175 The authors conclude that WBC counts in the elderly are associated with prevalent

176 At each site and in each year, WBC counts in the Plasmodium falciparum-infected patient

177 greatly reduced peripheral white blood cell (WBC) counts in leukemia recipient mice and induced apopt

178 residual disease (MRD) and white blood cell (WBC) counts, in both adult and pediatric cohorts.

179 A > 1 SD WBC count increase during CRRT did not significantly inc

180 d ratio (LR) increased as the synovial fluid WBC count increased (for counts <25,000/microL: LR, 0.32

181 compared with baseline: in the control arm, WBC count increased (mean 21.1%; 27.6% had a >20% increa

182 The results support incorporation of WBC count into PV risk stratification and studies of tre

183 The WBC count is a clinical marker of inflammation and a str

184 WBC count is also a complex trait that varies among indi

185 An increasing WBC count is associated with a significantly higher risk

186 Total WBC count is confirmed to be an independent predictor of

187 An elevated WBC count is directly associated with increased incidenc

188 portance universally acknowledged, access to WBC counts is largely limited to those with access to ph

189 White blood cell (WBC) count is a common clinical measure used as a predic

190 Elevated white blood cell (WBC) count is associated with increased major adverse ca

191 d efficient measurement of white blood cell (WBC) counts is vital for monitoring general patient heal

192 9 years of age at diagnosis with an initial WBC count less than 10,000/microL, were eligible for thi

193 26-treated mice achieved a white blood cell (WBC) count less than 20.0 x 10(9)/L (20,000/microL) at n

194 25 low- risk patients (WBC count < 10,000/microl) received ATRA (45 mg/m2 daily

195 anced by CYC-induced reductions in the total WBC count < 3,000 cells/microliter and by sequential IV

196 of 46%, whereas the 58 patients (30%) with a WBC count <200 x 10(9)/L, gLoR classifier, and MRD <10(-

197 io [HR] = 0.58, P = .002), white blood cell (WBC) count <10 x 10(9)/L (HR = 0.60, P = .005), and ETV6

198 30% bone marrow blasts and white blood cell (WBC) counts </=15 x 109/L (AZA-AML-001 study).

199 <30%) or first leukopenia (white blood cell [WBC] count <3000 cells/mm), which required clinical inte

200 their counterparts in the lowest quartile of WBC count (<4,800 cells/mm(3)).

201 genotype and the cellular milieu defined by WBC counts may influence HIV disease course, and this ma

202 with higher values for the white blood cell (WBC) count (median 2,500/microL v 1,600/microL; P = .009

203 Current WBC counting method relies on bulky instrument and train

204 (WT) or Tet2(+/-) BM cells, led to increased WBC counts, monocytosis, and splenomegaly in WT recipien

205 Patients with a WBC count more than 200,000/microL at diagnosis and an M

206 WBC count more than 50,000/microL was an adverse prognos

207 f chemotherapy, and B-precursor disease with WBC counts more than 100,000/microL all relapsed unless

208 chronic disease, increased HOMA-IR, a higher WBC count, more physical activity, and excessive sleep.

209 EVI1(-) t(9;11) AMLs had lower WBC counts, more commonly FAB M5 morphology, and frequen

210 up by the investigators because of decreased WBC counts, mostly outside of study protocol criteria, d

211 gnostic factors such as cytogenetic risk and WBC count, neither the presence of EMD nor the number of

212 up displayed a significantly increased total WBC count, neutrophil count, and percent neutrophils com

213 Circulating white blood cell (WBC) counts (neutrophils, monocytes, lymphocytes, eosino

214 ered from MLD(-) patients only by lower mean WBC counts, not by biologic characteristics, cytogenetic

215 on a bone marrow biopsy performed for a low WBC count (odds-ratio = 0.55 per standard deviation incr

216 Fourteen patients (8.0%) had a WBC count of >50.0 x 10(9)/microL.

217 tients experienced leukopenia, with a median WBC count of 2,900 (range, 800 to 3,900) at nadir.

218 arasite densities on the basis of an assumed WBC count of 8000 cells/microL.

219 L or higher (DFS, 40% v 0%) and those with a WBC count of less than 20 x 10(9)/L (DFS, 73% v35%), (2)

220 gnostic factors were age less than 3 months, WBC count of more than 50,000/microL, CD10 negativity, s

221 h of the P. falciparum-infected patients had WBC counts of <4000 cells/microL.

222 ed idarubicin because of a white blood cell (WBC) count of more than 30 000/microL.

223 and had median presenting white blood cell (WBC) counts of 10 950/microL (range, 2900-70 300/microL)

224 ne the association between white blood cell (WBC) count on admission and 30-day mortality in patients

225 L, such as older age, high white blood cell (WBC) count, organomegaly, T-lineage immunophenotype, abi

226 evaluated the relationship between baseline WBC count, other baseline variables and biomarkers, angi

227 des evidence for a secular downward trend in WBC count over the period from 1958 to 2002.

228 Higher CRP (P < 0.001), WBC count (P < 0.001), fibrinogen (P < 0.001), and facto

229 2), hematocrit levels (P = 9.5 x 10(-7)) and WBC count (P = 3.1 x 10(-5)).

230 Children had significantly higher baseline WBC counts (P < .001).

231 n, including decreased CSF white blood cell (WBC) count (P < .001), interleukin (IL)-4 (P = .02), IL-

232 or the association of S-form type and higher WBC count; P = .40).

233 acteremia, altered liver function, increased WBC counts, pathogen-specific Ab (IgM and IgG), and cell

234 Effect size represents change in transformed WBC counts per change in log odds-ratio of the disease.

235 I, 8.26-10.49), and higher white blood cell (WBC) count (per 1000/muL: beta = 0.95; 95% CI, 0.74-1.16

236 ransplantation, diagnostic white blood cell (WBC) count, Ph chromosome status, and ploidy was 6.0% hi

237 There was a significant change in WBC count postprocedure compared with baseline: in the c

238 provements in CSF glucose, white blood cell (WBC) count, protein, cellular and soluble inflammatory m

239 A high WBC count, raised serum ALT, raised serum total bilirubi

240 or 10 days, until the peak white blood cell (WBC) count reached 75x109/L, until discharge from the ho

241 PBSC collections were initiated when the WBC count recovered to greater than 1 x 10(9)/L.

242 or patients with low, intermediate, and high WBC counts, respectively (p = 0.0017).

243 However, the equipment necessary to perform WBC counts restricts their operation to centralized labo

244 Distributions of sex, age, race, presenting WBC count, risk group, treatment arm, and compliance wit

245 vival in a univariate analysis included age, WBC count, Sanz classification, and percent blood blasts

246 Age, WBC count, secondary AML, Eastern Cooperative Oncology G

247 Limited data exist on the WBC count secular trend and the relationship between WBC

248 ia chromosome status, age, white blood cell (WBC) count, sex, race, and ploidy group (P =.01).

249 icant associations between 3 AI diseases and WBC counts: systemic lupus erythematous (Beta = - 0.05 [

250 sed artery at 60 and 90 minutes had higher a WBC count than patients with an open artery (P:=0.02).

251 chomatis infection had a 0.43 log(10) higher WBC count than their HIV-uninfected, chlamydia-positive

252 ry, on average, have lower white blood cell (WBC) counts than those of European descent (ethnic leuko

253 mained high, and normal or elevated pre-CRRT WBC count that increased.

254 elet count that decreased, pre-CRRT elevated WBC count that remained high, and normal or elevated pre

255 whereas animals injected with PYKK081 had a WBC count that resembled that of the uninfected control.

256 BMB with a clinical history of isolated low WBC counts, the rs2814778-CC genotype was highly prevale

257 nd differential peripheral white blood cell (wbc) counts, together with full mouth plaque and gingivi

258 es were ELN risk group and white blood cell (WBC) counts; treatment with midostaurin had no influence

259 tinental-BFM 2002 study on the basis of age, WBC count, unfavorable genetic aberrations, and treatmen

260 r, we present a method to obtain an accurate WBC count using a patterned dried blood spot (pDBS) card

261 first apheresis performed when the recovery WBC count was > or = 5.0 x 10(9)/L.

262 The median nadir WBC count was 1.4 x 10(3)/microL.

263 Her WBC count was 10,370/muL, with a differential showing 5%

264 The weighted mean WBC count was 7,130 cells/uL, with the WBC 5-part differ

265 myocardial infarction (NSTEMI) and to see if WBC count was a significant predictor of outcomes indepe

266 on between bivalirudin therapy and admission WBC count was apparent for 1-year mortality.

267 In addition, a higher WBC count was associated with poorer TIMI myocardial per

268 Elevation in WBC count was associated with reduced epicardial blood f

269 patients enrolled in the HORIZONS-AMI trial, WBC count was available in 3433 (95.3%) patients.

270 After adjustment for confounding factors, WBC count was found to be a strong independent predictor

271 Collections were initiated when the WBC count was greater than 10 x 10(9)/L or 4 days after

272 WBC count was independently associated with somatic depr

273 WBC count was measured at baseline in 160,117 postmenopa

274 The WBC count was nonlinearly associated with all-cause mort

275 A downward trend in WBC count was observed from 1958 to 2002.

276 A higher baseline WBC count was predictive of higher six-month mortality,

277 Elevated WBC count was significantly associated with initial TE o

278 A predisposition to lower WBC counts was associated with a decreased risk of ident

279 A predisposition to benign lower WBC counts was associated with an increased risk of disc

280 The median white blood cell (WBC) count was 1,450/microL at diagnosis and was 31,000/

281 Average white blood cell (WBC) count was 37.7 x 10(9)/microL.

282 High deciles of both baseline and mean WBC count were positively associated with total mortalit

283 Lower albumin and %LYM and a higher WBC count were significantly associated with outcomes.

284 Lower haemoglobin (Hb) and high WBC counts were also significantly different between the

285 Higher baseline WBC counts were associated with lower Thrombolysis In My

286 PLT and WBC counts were both inversely related to MD adherence (

287 Higher WBC counts were significantly associated with positive b

288 perative level for 1 year posttransplant and WBC counts were significantly lower for 3 years after tr

289 WBC counts were statistically significantly higher in pe

290 and HIV disease markers or white blood cell (WBC) count were examined using mixed-effects and linear

291 red blood cells (RBC) and white blood cell (WBC) counts were found to increase significantly after b

292 n a simple, widely available blood test, the WBC count, were associated with impaired epicardial and

293 nce status, lactate dehydrogenase level, and WBC count, were confirmed as independent prognostic fact

294 .04), an increased risk of leukopenia (a low WBC count) when treated with a chemotherapeutic (n = 172

295 antly elevated circulating white blood cell (WBC) count, whereas animals injected with PYKK081 had a

296 The association of WBC count with mortality was independent of smoking and

297 th Initiative to examine the associations of WBC count with total mortality, CHD mortality, and cance

298 ith electrocardiogram, and white blood cell (WBC) counts with hematology analyzer.

299 to keep the platelet count, and arguably the WBC count, within the normal range.

300 and magnetic techniques to provide accurate WBC counts without blood extraction.